miR-5000-3p confers oxaliplatin resistance by targeting ubiquitin-specific peptidase 49 in colorectal cancer

Colorectal cancer (CRC) is the most common form of gastrointestinal malignancies. A growing number of reports focusing on oxaliplatin (OXA) resistance in CRC treatment have revealed that drug resistance is an urgent issue in clinical applications, especially for finding effective therapeutic targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Yan-yan, Zhong, Wa, Xia, Zhong-sheng, Lin, Shu-zhen, Chan, Man chung, Jiang, Ke, Li, Wen-fei, Xu, Xin-yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169888/
https://www.ncbi.nlm.nih.gov/pubmed/34075026
http://dx.doi.org/10.1038/s41420-021-00494-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169888/
https://www.ncbi.nlm.nih.gov/pubmed/34075026
http://dx.doi.org/10.1038/s41420-021-00494-0

Ejemplares similares